Grove Bank & Trust Sells 691 Shares of Sanofi (NASDAQ:SNY)

Grove Bank & Trust decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 12.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,000 shares of the company’s stock after selling 691 shares during the quarter. Grove Bank & Trust’s holdings in Sanofi were worth $241,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Barrow Hanley Mewhinney & Strauss LLC increased its position in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC grew its stake in shares of Sanofi by 1,153.1% during the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after buying an additional 2,306,286 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after buying an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Sanofi by 28,890.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after acquiring an additional 1,424,289 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

SNY opened at $50.74 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company’s 50 day moving average price is $48.46 and its two-hundred day moving average price is $52.11. The firm has a market capitalization of $128.77 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 1.17 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.55 earnings per share. As a group, research analysts predict that Sanofi will post 3.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.